Experimental COVID-19 Vaccines Expand Phase 3 Studies

The global COVID-19 vaccine development landscape includes innovative platforms such as nucleic acid, virus-like particle, peptide, viral vector, recombinant protein, live attenuated virus, and inactivated virus approaches says the U.S. FDA. The goal of these vaccines is to prevent the SARS-CoV-2 virus from getting into cells, replicating itself, which then infects a person, causing COVID-19.

As of November 15, 2020, the FDA had not issued emergency authorization for any experimental COVID-19 vaccine candidate.